par Marechal, Raphaël
;Mackey, John R;Lai, Raymond;Demetter, Pieter
;Peeters, Marc;Polus, Marc;Cass, Carol E;Salmon, Isabelle
;Devière, Jacques
;Van Laethem, Jean-Luc 
Référence Cancer, 116, 22, page (5200-5206)
Publication Publié, 2010-11





Référence Cancer, 116, 22, page (5200-5206)
Publication Publié, 2010-11
Article révisé par les pairs
Résumé : | Gemcitabine (2',2'-difluorodeoxycytidine) administration after resection of pancreatic cancer improves both disease-free survival (DFS) and overall survival (OS). Deoxycytidine kinase (dCK) mediates the rate-limiting catabolic step in the activation of gemcitabine. The authors of this report studied patient outcomes according to the expression of dCK after a postoperative gemcitabine-based chemoradiation regimen. |